CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 02/11/20

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this Read more ...

BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the B...

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this Read more ...

– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors  and CYC065-venetoclax combination in AML /MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (...

Will These Be The Best Penny Stocks To Trade Next Week? At the end of each week, it’s always good to take inventory. When it comes to trading penny stocks , this involves analyzing the week you’ve just completed. It also takes into account a strategy for “next week.ȁ...

BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biote...

BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, today announced study design and preliminary data from t...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2019 Earnings Conference Call November 13, 2019 4:30 PM ET Company Participants Jan Medina – Russo Partners LLC Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President-Finance an...

Cyclacel Pharmaceuticals (NASDAQ: CYCC ): Q3 GAAP EPS of -$0.11 beats by $0.04 . Cash and cash equivalents of $12.96M Press Release More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, ...